Eplerenone (Inspra)

A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.

Also Known As:

Inspra; 9,11-Epoxy-7-(methoxycarbonyl)-3-oxo-17-pregn-4-ene-21,17-carbolactone; Eplerenon; Spiro(cyclopenta(7,8)phenanthro(4b,5-b)oxirene-7(3H),2'(3'H)-furan)-10-carboxylic acid, 2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-4a,6a-dimethyl-2,5'-dioxo-, methyl ester, (4aS,4bR,5aR,6aS,7 R,9aS,9bR,10R)-

Networked: 865 relevant articles (141 outcomes, 308 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Pitt, Bertram: 70 articles (04/2022 - 04/2002)
2.	Zannad, Faiez: 55 articles (04/2022 - 04/2003)
3.	Rossignol, Patrick: 31 articles (04/2022 - 05/2009)
4.	Vincent, John: 29 articles (04/2022 - 08/2005)
5.	McMurray, John J V: 29 articles (03/2022 - 06/2009)
6.	Krum, Henry: 25 articles (01/2017 - 10/2002)
7.	Swedberg, Karl: 20 articles (01/2021 - 06/2005)
8.	van Veldhuisen, Dirk J: 20 articles (01/2021 - 08/2005)
9.	Ferreira, João Pedro: 18 articles (04/2022 - 01/2018)
10.	Shi, Harry: 15 articles (12/2018 - 08/2008)

Related Diseases

1.	Heart Failure 08/01/2012 - "Eplerenone is publicized to be extremely effective in reducing mortality from heart failure, with a reasonable side-effect profile. " 11/01/2004 - "New treatment option for heart failure patients: eplerenone." 07/01/2019 - "We undertook a secondary analysis of data from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure study to assess if clinical outcomes, as well as the efficacy of eplerenone, varied according to heart rate at baseline. " 12/01/2015 - "Treatment with eplerenone has been associated with decreased blood pressure and improved survival for patients with heart failure and reduced left ventricular ejection fraction. " 04/01/2015 - "Clinical Development and Regulatory Approval of Acute Heart Failure Drugs in Japan : Editorial to: "Rationale and Design of Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)" by M. "
2.	Hypertension (High Blood Pressure) 01/01/2018 - "This patient-level pooled analysis provides robust evidence that eplerenone, at 50 mg or 100 mg daily, was effective in lowering BP in patients with mild-to-moderate hypertension and was well tolerated." 12/01/2016 - "In patients with drug-resistant hypertension, add-on use of eplerenone was effective in lowering BP, especially home and ambulatory awake BP." 12/01/2016 - "Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension." 10/01/2002 - "In humans, eplerenone appears to be effective for the treatment of hypertension. " 08/01/2002 - "Eplerenone doses of 50 to 400 mg once daily are well tolerated and effective in reducing BP in patients with mild-to-moderate hypertension during a 24-h period."
3.	Myocardial Infarction 01/01/2018 - "The present study confirms the protective effects of eplerenone on myocardial infarction in diabetic rats via modulation of PI3K/Akt pathway and its downstream regulator GSK-3β." 01/01/2015 - "Together, our study provides evidence for protective effects of eplerenone on myocardium in experimentally induced myocardial infarction. " 11/01/2019 - "Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial." 01/01/2010 - "The incremental cost effectiveness of eplerenone in cost per life-year gained (LYG) and cost per quality-adjusted life-year (QALY) gained beyond the trial period was estimated using data from the Framingham Heart Study, the Saskatchewan Health database, and the Worcester Heart Attack Registry. " 11/01/2005 - "Life-years gained in the eplerenone arm during the trial period were extrapolated to lifetime life-years gained using three sources of life expectancy data (Framingham Heart Study, Saskatchewan Health Database and Worcester Heart Attack Registry). "
4.	Left Ventricular Dysfunction 12/03/2002 - "The present study examined the effects of long-term monotherapy with eplerenone on the progression of LV dysfunction and remodeling in dogs with chronic HF. " 01/01/2021 - "Eplerenone 25 mg/day was also initiated due to a left ventricular dysfunction. " 05/01/2014 - "Eplerenone failed to improve left ventricular systolic dysfunction or chamber enlargement. " 06/01/2009 - "Eplerenone failed to prevent left ventricular systolic dysfunction or chamber enlargement in RVP dogs. " 05/01/2006 - "Because of the prognostic importance of LV dysfunction following an AMI and the increasing use of electrical and/or mechanical interventions in patients with LV systolic dysfunction, this retrospective analysis of EPHESUS patients with LVEF <or=30% at baseline was conducted to determine the value of eplerenone in this setting. "
5.	Central Serous Chorioretinopathy 10/01/2021 - "Background The study examined the efficacy of eplerenone in the management of chronic central serous chorioretinopathy (CSCR) with the aim of short-term observations. " 01/01/2021 - "The VICI trial reported by Lotery et al. is a recent placebo-controlled, randomized trial that examined the efficacy of eplerenone treatment for chronic central serous chorioretinopathy (CSCR) in 104 patients. " 01/01/2020 - "Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy." 11/01/2019 - "To determine the efficacy of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy (CSCR). " 11/01/2019 - "Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy."

Related Drugs and Biologics

1.	Spironolactone (Aldactone)
2.	Mineralocorticoid Receptor Antagonists
3.	Aldosterone
4.	Antihypertensive Agents (Antihypertensives)
5.	Mineralocorticoid Receptors (Mineralocorticoid Receptor)
6.	Salts
7.	finerenone
8.	Diuretics
9.	candesartan
10.	Mineralocorticoids

Related Therapies and Procedures

1.	Therapeutics
2.	Patient Readmission
3.	Ligation
4.	Adrenalectomy
5.	Sodium-Restricted Diet (Diet, Sodium Restricted)